Clinical and pathogenetic substantiation of application meglumine sodium succinate in the treatment of patients with erysipelas

• Lyudmila I. Ratnikova
• Stepan A. Ship

Abstract

Aim - to determination of the drug effectiveness meglumini natrii succinas in patients with erysipelas.

Material and methods. An clinical trial with the inclusion of 170 patients with erysipelas. By random distribution, patients were divided into two comparable groups: 1^st group (81 patients) received standard therapy + meglumini natrii succinas; 2^nd group (89 patients) received only standard therapy. Clinical efficacy of various treatment options was assessed by the rate of relief of the syndrome of general intoxication and the syndrome of local inflammatory changes. In addition, the effect of various treatment regimens on the dynamics of changes in laboratory parameters reflecting the intensity of the processes of lipid peroxidation (LPO) and activity of antioxidant system (AOS) - LPO/AOS - was analyzed.

Results. Use meglumini natrii succinas of preparation in case of erysipelas is reliably (p<0,05) shortens the duration of the syndrome of general intoxication (in case of mild course - by 22%; in severe course - by 18%), shortens the duration of the syndrome of local inflammatory changes (in case of mild course - by 17%; in severe course - by 19%). The dual (antioxidant and pro-oxidant) effects of MNS in patients with erysipelas have been established, which is consistent with the facts described in the literature when the widely used antioxidants (alpha-lipoic acid, ethylmethylhydroxypyridine succinate, ascorbic acid) are capable of potentiating free radical oxidation processes, revealing the properties of pro-oxidants.

Conclusion. High clinical efficacy meglumini natrii succinas of in patients with erysipelas was demonstrated.

Keywords:erysipelas, meglumini natrii succinas, clinical trial, free radical oxidation, lipid peroxidation, antioxidant system

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)